Kiora Pharmaceuticals (KPRX) Total Current Liabilities (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Total Current Liabilities came in at $2.8 million in Q1 2026, down 46.95% YoY from $5.3 million in Q1 2025, and down 22.94% on a QoQ basis from $3.6 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Total Current Liabilities (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Total Current Liabilities data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Total Current Liabilities fell 46.95% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 46.95% YoY) and the FY2025 annual result came in at $3.6 million, down 39.56% from the prior year.
- Total Current Liabilities declined to $2.8 million in Q1 2026, from $3.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $6.0 million in Q4 2024 to a low of $1.6 million in Q1 2024.
- A 5-year average of $2.9 million and a median of $2.8 million in 2026 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 1310.58% — and 2023, when it slumped 50.07%.
- Tracing KPRX's Total Current Liabilities over 5 years: stood at $3.3 million in 2022, then tumbled by 50.07% to $1.6 million in 2023, then surged by 267.73% to $6.0 million in 2024, then sank by 39.56% to $3.6 million in 2025, then decreased by 22.94% to $2.8 million in 2026.
- The last three Total Current Liabilities figures came in at $2.8 million (Q1 2026), $3.6 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 630.93 Mn |
| 10 | Kiora Pharmaceuticals | 16.19 Mn | 16.19 Mn | - | 2.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.37 Mn |
| Mar 31, 2026 | 2.80 Mn |
| Dec 31, 2025 | 3.63 Mn |
| Sep 30, 2025 | 2.58 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Mar 31, 2025 | 5.27 Mn |
| Dec 31, 2024 | 6.01 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 1.88 Mn |
| Mar 31, 2023 | 2.16 Mn |
| Dec 31, 2022 | 3.27 Mn |
| Sep 30, 2022 | 2.99 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 2.52 Mn |
| Dec 31, 2021 | 1.61 Mn |
| Sep 30, 2021 | 212,281.00 |